17 December 2025 - The approval marks the first new stroke treatment authorised in nearly 27 years, offering an additional option for managing acute ischaemic stroke in Canada.

Roche Canada is proud to announce that Health Canada has granted market authorisation for TNKase (tenecteplase), a thrombolytic agent, effective 13 November 2025 for the treatment of acute ischaemic stroke in adults.

Read Roche press release